Nurix Therapeutics, Inc.
BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF

Last updated:

Abstract:

The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.

Status:
Application
Type:

Utility

Filling date:

5 May 2021

Issue date:

18 Nov 2021